[go: up one dir, main page]

BRPI0406778A - Antagonistas de receptores de androgênio - Google Patents

Antagonistas de receptores de androgênio

Info

Publication number
BRPI0406778A
BRPI0406778A BR0406778-9A BRPI0406778A BRPI0406778A BR PI0406778 A BRPI0406778 A BR PI0406778A BR PI0406778 A BRPI0406778 A BR PI0406778A BR PI0406778 A BRPI0406778 A BR PI0406778A
Authority
BR
Brazil
Prior art keywords
androgen receptor
receptor antagonists
sulfonamido
androgen
antagonists
Prior art date
Application number
BR0406778-9A
Other languages
English (en)
Inventor
Daniel Yunlong Du
Matthew Colin Thor Fyfe
Martin James Procter
Karen Lesley Schofield
Vilasben Kanji Shah
Geoffrey Martyn Williams
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0406778A publication Critical patent/BRPI0406778A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"ANTAGONISTAS DE RECEPTORES DE ANDROGêNIO". A presente invenção refere-se a uma nova classe de derivados de 6-sulfonamido-quinolin-2-ona e de 6-sulfonamido-2-oxo-cromeno, ao seu uso como antagonistas de androgênio, e às condições a aliviar, associadas à ativação inapropriada do receptor de androgênio.
BR0406778-9A 2003-01-17 2004-01-08 Antagonistas de receptores de androgênio BRPI0406778A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44104903P 2003-01-17 2003-01-17
PCT/IB2004/000094 WO2004065379A1 (en) 2003-01-17 2004-01-08 Androgen receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0406778A true BRPI0406778A (pt) 2006-01-17

Family

ID=32771896

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406778-9A BRPI0406778A (pt) 2003-01-17 2004-01-08 Antagonistas de receptores de androgênio

Country Status (7)

Country Link
US (1) US7064207B2 (pt)
EP (1) EP1587804A1 (pt)
JP (1) JP2006515605A (pt)
BR (1) BRPI0406778A (pt)
CA (1) CA2511089A1 (pt)
MX (1) MXPA05007605A (pt)
WO (1) WO2004065379A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200628446A (en) * 2004-12-14 2006-08-16 Takeda Pharmaceuticals Co Substituted pyrrole derivative
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
JP2009079039A (ja) * 2007-09-05 2009-04-16 Sumitomo Chemical Co Ltd クマリン化合物及びその用途
JP2009084269A (ja) * 2007-09-05 2009-04-23 Sumitomo Chemical Co Ltd クマリン化合物及びその用途
JP2009062300A (ja) * 2007-09-05 2009-03-26 Sumitomo Chemical Co Ltd クマリン化合物及びその用途
US9487780B2 (en) 2012-06-01 2016-11-08 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
US9828602B2 (en) 2012-06-01 2017-11-28 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
CN103127112A (zh) * 2013-02-27 2013-06-05 江苏先声药物研究有限公司 一类喹啉酮衍生物在肿瘤治疗中的应用
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
WO2016004180A1 (en) * 2014-07-01 2016-01-07 President And Fellows Of Harvard College O-glcnac transferase (ogt) inhibitors and uses thereof
BR112019000706A8 (pt) 2016-07-15 2022-12-06 Pasteur Institut Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
JP2021195368A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
CN116327765A (zh) * 2023-03-27 2023-06-27 广州许愿树毛发医学科技有限公司 莲心碱类化合物作为β2-肾上腺素受体阻断剂的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT79699B (en) * 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
WO1997049709A1 (en) * 1996-06-27 1997-12-31 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
AU2298899A (en) * 1998-02-05 1999-08-23 Takeda Chemical Industries Ltd. Sulfonamide derivatives, process for producing the same and utilization thereof
BR0013597A (pt) 1999-08-27 2002-07-16 Ligand Pharm Inc Compostos e métodos moduladores de receptor de androgênio
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
US7214690B2 (en) * 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
AU2003230869B2 (en) * 2002-04-26 2010-02-25 Ortho-Mcneil Pharmaceutical, Inc. 2-(quinolonyl)-fused heterocycles as androgen receptor modulators

Also Published As

Publication number Publication date
CA2511089A1 (en) 2004-08-05
US7064207B2 (en) 2006-06-20
EP1587804A1 (en) 2005-10-26
JP2006515605A (ja) 2006-06-01
US20050085467A1 (en) 2005-04-21
WO2004065379A1 (en) 2004-08-05
MXPA05007605A (es) 2005-09-30

Similar Documents

Publication Publication Date Title
BRPI0406778A (pt) Antagonistas de receptores de androgênio
MA33782B1 (fr) Composés insecticides à base de dérivés isoxazoline
BRPI0816128A2 (pt) Uso de uma composição de estabilização, composição de estabilização, produto de cuidado corporal, e, produto doméstico.
BRPI0813218A2 (pt) Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
ATE363250T1 (de) Wirbelsäulenprothesen
MX2009009690A (es) Derivados de tiazolidina como antagonistas del receptor de orexina.
PL2065065T3 (pl) Dozownik dla wstrzykiwacza
CY1110753T1 (el) Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i
CO6170406A2 (es) Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
BRPI0717266A2 (pt) Derivados de oxindol
PL1904000T3 (pl) Bandaż, zwłaszcza jako element nośny ortezy
ATE502006T1 (de) Alkyl-, alkenyl- und alkynylcarbamat-derivate, deren herstellung und therapeutische verwendung
UY28855A1 (es) Derivados de la 1-amino-ftalazina su preparación y su uso en terapia
SV2008002952A (es) Uso de derivados de sulfamida heterociclica benzo-fusionada para el tratamiento de obesidad referencia cruzada a solicitudes relacionadas ref. prd2586sv
MA32537B1 (fr) Dérivés de pyrazolo [5,1-b] oxazole en tant qu'antagonistes de crf1
MX2010005602A (es) Uso de combinaciones de principios activos para combatir parasitos animales.
SV2005002061A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538
TW200744612A (en) New combination
ATE496234T1 (de) Bauteil mit innen- und aussenverzahnung
BRPI0607404A2 (pt) compostos de cinolina e seu uso como moduladores de receptor de x hepático
AR070456A1 (es) Combinacion que comprende paclitaxel para el tratamiento de cancer de ovario y su uso
DE602006016258D1 (de) 4h-1,2,4-triazin-5-on-derivate, ihre herstellung und ihre verwendung als alpha-7-nikotin-acetylcholin-rezeptoren
PH12018502733A1 (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
MX2010001304A (es) Compuestos terapeuticos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.